The Human Microbiome Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Big Pharma Players Striving To Gain Market Entry Through Collaboration with Microbiome Players
There has been a growing interest from the big pharma players in microbiome research. Many of the big pharma players have been supporting the start-up microbiome players for their clinical drug candidate through funding and collaborations. For instance, in July 2022, Enterome a clinical stage microbiome company signed a strategic R&D collaboration with Nestle Health Science. This license agreement primarily targeted food allergy and Inflammatory Bowel Disease (IBD) under this agreement Enterome will receive an upfront payment of €40 million (US$46.9 million) in cash and equity. In return, Nestle Health Science will be eligible to receive the royalties and sales milestone payments on commercialization of the drug candidates. In February 2021, 4D Pharma Inc. has collaborated with Merck Co Ltd. and Pfizer for its oncology and vaccines to evaluate its MRx5018 in combination with BAVENCIO for treatment of locally advanced or metastatic urothelial carcinoma. Both Merck KGaA and Pfizer Inc. will co-develop and also commercialize it in collaboration. Similarly, in January 2021, Vedanta Biosciences has received US$25 million investment fund from Pfizer as a part of breakthrough growth initiative. Vedanta will use these funds for Phase II study of VE202 indicated for treatment of Inflammatory Bowel Disease. In July 2021, Seres announced its collaboration with Nestle Health Science to co-commercialize SER-109 therapeutic drug for treatment of Clostridioides difficile infection (CDI) in U.S. and Canada. In 2019, Seres had collaborated with AstraZeneca and received US$20 million as a financial support to conduct its research activity for immuno-oncology therapies. With more pharma players are entering this market, the overall market for human microbiome is expected to foresee a staggering growth during the forecast period.Regulatory Approvals to Challenge Market Growth
The human microbiome has a huge potential in curing and treating diseases that have been difficult to treat through conventional methods. Moreover, the use of Live Biotherapeutic Products (LBPs) has been studied to be of great potential, however lack of defined regulatory approvals for human microbiomes is hampering the growth of this market. There has not been any clearly defined segregation for LBPs and their use, especially when classifying prebiotics, probiotics, and pharmaceutical products. The U.S. FDA in 2010, first time presented draft guidance for microorganisms intended to prevent and treat diseases which got updated in 2016 to officially make a category for LBPs. Similarly, the European Pharmacopeia Commission issued a draft in 2019 with a mention of LBPs to comply with the legislation of biological medicinal products with additional specific guidelines for LBPs. There has been a clear demand from the regulatory authorities regarding the benefits against the risks of LBPs. Conventional GMP practices emphasize the removal of microbes in the final product however, human microbiome products need to be in the final product. Hence, drafting new guidelines for regulatory approvals needs detailed documentation and justification as these products differ from non-therapeutic products. Risk assessment through genomic profiling is crucial as the LBPs have the potential to transfer genes to other microbes or may metabolize other drugs or hormones in the body. To avoid this, in vitro and ex-vivo studies, and animal models studies are essential. Detailed documentation of the origin of the strain, isolation procedure, and cell banking is required. In addition, the difficulty in having consistent batches of LBPs is also a major GMP regulatory hurdle. We believe, that as the market expands there will be well-defined regulatory guidelines for conducting human microbiome studies, at present the approval process poses a major challenge for the market players of this segment.What Questions Should You Ask before Buying a Market Research Report?
- How is the human microbiome market evolving?
- What is driving and restraining the human microbiome market?
- How will each human microbiome submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
- How will the market shares for each human microbiome submarket develop from 2023 to 2033?
- What will be the main driver for the overall market from 2023 to 2033?
- Will leading human microbiome market broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
- Who are the leading players and what are their prospects over the forecast period?
- What are the human microbiome drug pipeline status for these leading companies?
- How will the industry evolve during the period between 2023 and 2033? What are the implications of human microbiome market projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the human microbiome market?
- Where is the human microbiome market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the human microbiome market today, and over the next 10 years:
- Our 281-page report provides 121 tables and 168 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2033 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2033, the new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), and recent developments.
Segments Covered in the Report
By Therapeutics
- Gastrointestinal Disorders
- Infectious Diseases
- Metabolic Disorders
- Cancers
- Gut-Brain Axis
- Others
By Type
- Fecal Microbiota Transplant (FMT)
- Live Biotherapeutic Product (LBP)
- Prebiotics
- Post-Biotics
- Precision Antibiotics
By Product
- Prebiotics & Probiotics
- Medicinal Drugs
- Diagnostic Tests
- Skin Microbiome
By Technology
- Genomics
- 16SrRNA Amplicon Sequencing
- Shotgun Metagenomic Sequencing
- Longread Metagenomic Sequencing
- Proteomics
- Metabolomics
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Taiwan
- Rest of Asia
Latin America
- Brazil
- Mexico
- Rest of Latin America
MEA
- Saudi Arabia
- South Africa
- UAE
- Rest of Middle East & Africa
Leading companies and the potential for market growth
- 4D Pharma Plc.
- Axial Therapeutics
- BiomX
- Enterobiome
- Enterome
- Finch Therapeutics Group Inc.
- MaaT Pharma
- Rebiotix Inc.,( a Ferring Pharmaceutical Company)
- Second Genome
- Seres Therapeutics
- Synlogic
- Theriva Biologics (ex-Synthetic Biologics)
- Vedanta Biosciences Inc.
How will the Human Microbiome Market, 2023 to 2033 report help you?
In summary, this 280+ page report provides you with the following knowledge:- Revenue forecasts to 2033 for Human Microbiome Market, 2023 to 2033 Market, with forecasts by therapeutics, type, product, technology and company size, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2033 for five regional and 21 key national markets - See forecasts for the Human Microbiome, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Taiwan among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 13 of the major companies involved in the Human Microbiome Market, 2023 to 2033.
Information found nowhere else
With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Human Microbiome Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.Table of Contents
1 Report Overview
3 Market Overview
4 Human Microbiome Market Analysis by Therapeutics
5 Human Microbiome Market Analysis by Type
6 Human Microbiome Market Analysis by Product
7 Human Microbiome Market Analysis by Technology
8 Human Microbiome Market Analysis by Region
9 North America Human Microbiome Market Analysis
10 Europe Human Microbiome Market Analysis
11 Asia-Pacific Human Microbiome Market Analysis
12 Latin America Human Microbiome Market Analysis
13 Middle East & Africa Human Microbiome Market Analysis
14 Company Profiles
15 Conclusion and Recommendations
Companies Mentioned
- 4D Pharma Plc.
- Axial Therapeutics
- BiomX
- Enterobiome
- Enterome
- Finch Therapeutics Group Inc.
- MaaT Pharma
- Rebiotix Inc.,( a Ferring Pharmacetical Company)
- Second Genome
- Seres Therapeutics
- Synlogic
- Theriva Biologics (ex-Synthetic Biologics)
- Vedanta Biosciences Inc.
- Adaptive Phage Therapeutics
- ADM
- AsiaBiome
- Bacthera
- Beiersdorf
- Boehringer Ingelheim
- Holobiome
- Infant Bacterial Therapeutics
- Microba Life Sciences
- Microbiotica
- NovoBiome
- NuBiyota
- Osel
- Sensei Therapeutics
- Xbiome
- Biomedical Advanced Research and Development Authority (BARDA)
- California Institute of Technology
- Canadian Institute of Health Research (CHIR)
- Centro para el Desarrollo Tecnológico Industrial, Spain
- Food and Drug Administration (US FDA)
- France’s National Research Institute for Agriculture, Food and Environment (INRAE)
- German Research Foundation
- India Ministry of Science and Technology
- Instituto Nacional de Medicina Genómica (INMEGEN)
- Jansen Microbiome Research Center
- Madrid Science Park and National Center for Genomic Analysis (CNAG)
- National Committee for Biosafety, Biosecurity and Life Sciences (CNBBSV)
- National Institute of Agricultural Research (INIA)
- National Institute of Health (NIH)
- National Institutes of Science and Technology (INCT), Brazil
- Sau Paulo Research Foundation (FAPESP)
- The African Microbiome Institute (AMI)
- The Biological Sciences Research Council (BBSRC)
- The Combating Antibiotic Resistant Bacteria (CARB-X)
- The Japan Microbiome Consortium